Cardio Diagnostics Holdings reported revenue of $34,890 for FY2024, representing a 104% increase from $17,065 in FY2023. The company posted a net loss of $8.38 million, comparable to the prior year's loss of $8.38 million. General and administrative expenses increased to $8.17 million from $6.94 million in 2023, primarily due to higher stock compensation expenses.The company strengthened its financial position through an At-the-Market offering, raising $14.68 million net proceeds through March 20, 2025. Strategic developments included receiving Medicare pricing determination from CMS for its PrecisionCHD and Epi+Gen CHD tests, expanding test availability through retail clinical locations, and establishing partnerships with seven new provider organizations.The company faces a Nasdaq compliance challenge regarding minimum bid price requirements, with a deadline of June 2, 2025 to regain compliance. Looking ahead, Cardio plans to focus on developing additional products, expanding clinical evidence, leveraging newly awarded CPT codes, and scaling internal operations while pursuing strategic partnerships.

Cardio Diagnostics Holdings reported revenue of $34,890 for FY2024, representing a 104% increase from $17,065 in FY2023. The company posted a net loss of $8.38 million, comparable to the prior year's loss of $8.38 million. General and administrative expenses increased to $8.17 million from $6.94 million in 2023, primarily due to higher stock compensation expenses.The company strengthened its financial position through an At-the-Market offering, raising $14.68 million net proceeds through March 20, 2025. Strategic developments included receiving Medicare pricing determination from CMS for its PrecisionCHD and Epi+Gen CHD tests, expanding test availability through retail clinical locations, and establishing partnerships with seven new provider organizations.The company faces a Nasdaq compliance challenge regarding minimum bid price requirements, with a deadline of June 2, 2025 to regain compliance. Looking ahead, Cardio plans to focus on developing additional products, expanding clinical evidence, leveraging newly awarded CPT codes, and scaling internal operations while pursuing strategic partnerships.